Forcing Divestitures, FTC Gives Nod To Mylan Deal

Law360 (October 1, 2007, 12:00 AM EDT) -- The U.S. Federal Trade Commission has given the green light to pharmaceutical company Mylan Laboratories' $6.6 billion acquisition of generic-drug maker E. Merck OHG, but the commission forced the companies to sell five generic drugs they currently produce due to competition concerns.

After a 5-0 vote, the commission said Thursday that the companies would have to divest the five drugs to Amneal Pharmaceuticals LLC within 10 days.

“Mylan’s acquisition of Merck’s generic drug unit would result in reduced competition and higher prices for U.S. consumers of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.